 |
104 Diseases |  |
23 Trials |
|
23 Trials |  |
2308 News |  |
| «12...18192021222324252627282930 |
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) (clinicaltrials.gov) - Jan 8, 2012
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- | Victrelis (boceprevir) / Roche, Merck (MSD), Isentress (raltegravir) / Merck (MSD)
Trial completion: OPAL: Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (clinicaltrials.gov) - Dec 14, 2011
P1, N=24, Completed, Sponsor: Radboud University
Active, not recruiting --> Completed Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 (clinicaltrials.gov) - Dec 6, 2011
P2, N=10, Completed, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Recruiting --> Completed Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial initiation date: IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (clinicaltrials.gov) - Dec 5, 2011
P3, N=17, Completed, Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Active, not recruiting --> Completed Initiation date: Oct 2009 --> Jul 2010
- Isentress (raltegravir) / Merck (MSD)
New P3 trial, Monotherapy: Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors (clinicaltrials.gov) - Nov 27, 2011
P3, N=41, Active, not recruiting, Sponsor: IrsiCaixa
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers (clinicaltrials.gov) - Nov 16, 2011
P1, N=15, Completed, Sponsor: Angela Kashuba, PharmD
Initiation date: Oct 2009 --> Jul 2010 Recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial completion: A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=26, Completed, Sponsor: University of South Florida
Recruiting --> Completed Active, not recruiting --> Completed
- Fuzeon (enfuvirtide) / Roche, Isentress (raltegravir) / Merck (MSD)
Trial completion: RAL-eve Study: Raltegravir Substitution Study (clinicaltrials.gov) - Oct 26, 2011
P=N/A, N=14, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial withdrawal: Raltegravir Activity In Lymphoid Tissues (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=10, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Isentress (raltegravir) / Merck (MSD)
Trial completion: A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women (clinicaltrials.gov) - Oct 23, 2011
P=N/A, N=1, Completed, Sponsor: Kristine Patterson, MD
Active, not recruiting --> Withdrawn Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
New P4 trial: RASSTER: RAltegravir Switch STudy: Effects on Endothelial Recovery (clinicaltrials.gov) - Oct 16, 2011
P4, N=24, Recruiting, Sponsor: UMC Utrecht
- Isentress (raltegravir) / Merck (MSD)
New P3 trial: ANRS153TREVE: Renal Transplantation and Raltegravir in HIV-Infected Patients (clinicaltrials.gov) - Oct 13, 2011
P3, N=50, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Isentress (raltegravir) / Merck (MSD)
Trial completion: Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults (clinicaltrials.gov) - Oct 6, 2011
P2, N=113, Completed, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
New P4 trial: HANDral: A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV (clinicaltrials.gov) - Oct 5, 2011
P4, N=6, Terminated, Sponsor: St Vincent's Hospital, Sydney
- Isentress (raltegravir) / Merck (MSD)
Trial termination: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Sep 26, 2011
P3, N=0, Terminated, Sponsor: McGill University Health Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment.
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: RAG-1/2: Immune Responses in Patients Treated With Raltegravir (clinicaltrials.gov) - Sep 26, 2011
P3, N=0, Terminated, Sponsor: McGill University Health Center
Active, not recruiting --> Terminated; Unexpected and severe difficulties in recruitment. N=60 --> 0
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Discordant: Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product (clinicaltrials.gov) - Sep 26, 2011
P4, N=57, Completed, Sponsor: Germans Trias i Pujol Hospital
N=60 --> 0 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
New P1 trial: RIFRAL: The Effect of Intermittent Rifampicin on Raltegravir (clinicaltrials.gov) - Aug 25, 2011
P1, N=18, Completed, Sponsor: Helen Reynolds
- Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
New P2 trial: ROCnRAL: Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy (clinicaltrials.gov) - Aug 17, 2011
P2, N=48, Terminated, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)